Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T57001
|
||||
Former ID |
TTDR00892
|
||||
Target Name |
Cell surface A33 antigen
|
||||
Gene Name |
GPA33
|
||||
Synonyms |
A33 antigen; A33 cognate antigen; GPA33
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | ||||
Function |
May play a role in cell-cell recognition and signaling.
|
||||
BioChemical Class |
Immunoglobulin
|
||||
UniProt ID | |||||
Sequence |
MVGKMWPVLWTLCAVRVTVDAISVETPQDVLRASQGKSVTLPCTYHTSTSSREGLIQWDK
LLLTHTERVVIWPFSNKNYIHGELYKNRVSISNNAEQSDASITIDQLTMADNGTYECSVS LMSDLEGNTKSRVRLLVLVPPSKPECGIEGETIIGNNIQLTCQSKEGSPTPQYSWKRYNI LNQEQPLAQPASGQPVSLKNISTDTSGYYICTSSNEEGTQFCNITVAVRSPSMNVALYVG IAVGVVAALIIIGIIIYCCCCRGKDDNTEDKEDARPNREAYEEPPEQLRELSREREEEDD YRQEEQRSTGRESPDHLDQ |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
References | |||||
Ref 521702 | ClinicalTrials.gov (NCT00199797) Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | ||||
Ref 521801 | ClinicalTrials.gov (NCT00291486) Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | ||||
Ref 527624 | Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005 Jul 1;11(13):4818-26. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.